ESMO 2018 | Cetuximab for oropharyngeal cancer: latest data from De-ESCALaTE

Hisham Mehanna

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, FRCS(ORL-HNS), of the University of Birmingham, Birmingham, UK, presents at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Prof. Mehanna highlights data from the De-ESCALaTE trial comparing cetuximab vs. cisplatin in patients with HPV-positive, low-risk oropharyngeal cancer who are receiving radical radiotherapy (ISRCTN33522080; NCT01874171).

Share this video